Invesco
BCRX icon

Invesco’s BioCryst Pharmaceuticals BCRX Stock Holding History

Invesco’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5M Sell
1,308,813
-46,084
-3% -$358K ﹤0.01% 1714
2025
Q4 		$10.6M Buy
1,354,897
+392,521
+41% +$2.84M ﹤0.01% 1809
2025
Q3 		$7.3M Sell
962,376
-30,741
-3% -$256K ﹤0.01% 2022
2025
Q2 		$8.9M Buy
993,117
+24,962
+3% +$232K ﹤0.01% 1850
2025
Q1 		$7.26M Sell
968,155
-104,445
-10% -$842K ﹤0.01% 1967
2024
Q4 		$8.07M Buy
1,072,600
+67,492
+7% +$512K ﹤0.01% 1985
2024
Q3 		$7.64M Buy
1,005,108
+903,185
+886% +$6.87M ﹤0.01% 1987
2024
Q2 		$630K Buy
101,923
+2,512
+3% +$13.9K ﹤0.01% 3177
2024
Q1 		$505K Buy
99,411
+1,973
+2% +$11.1K ﹤0.01% 3333
2023
Q4 		$584K Sell
97,438
-2,497
-2% -$14.5K ﹤0.01% 3137
2023
Q3 		$708K Sell
99,935
-293
-0.3% -$2.1K ﹤0.01% 3031
2023
Q2 		$706K Buy
100,228
+3,328
+3% +$26.7K ﹤0.01% 3058
2023
Q1 		$808K Sell
96,900
-260,155
-73% -$2.5M ﹤0.01% 3002
2022
Q4 		$4.1M Sell
357,055
-5,547
-2% -$69.2K ﹤0.01% 2344
2022
Q3 		$4.57M Buy
362,602
+81,326
+29% +$1.05M ﹤0.01% 2274
2022
Q2 		$2.98M Buy
281,276
+57,996
+26% +$598K ﹤0.01% 2534
2022
Q1 		$3.63M Buy
223,280
+18,855
+9% +$302K ﹤0.01% 2530
2021
Q4 		$2.83M Sell
204,425
-3,939
-2% -$52.1K ﹤0.01% 2657
2021
Q3 		$3M Sell
208,364
-543,748
-72% -$8.58M ﹤0.01% 2624
2021
Q2 		$11.9M Sell
752,112
-681,726
-48% -$9.26M ﹤0.01% 1948
2021
Q1 		$14.6M Buy
1,433,838
+1,396,756
+3,767% +$14.4M ﹤0.01% 1733
2020
Q4 		$276K Buy
37,082
+25,188
+212% +$130K ﹤0.01% 3451
2020
Q3 		$41K Buy
11,894
+431
+4% +$1.85K ﹤0.01% 3606
2020
Q2 		$55K Buy
+11,463
New +$45.8K ﹤0.01% 3614
2019
Q3 		– Sell
-1,446,732
Closed -$5.48M – 3675
2019
Q2 		$5.48M Buy
1,446,732
+563,822
+64% +$3.39M ﹤0.01% 2120
2019
Q1 		$7.19M Sell
882,910
-121,815
-12% -$1.04M ﹤0.01% 1755
2018
Q4 		$8.11M Buy
1,004,725
+115,333
+13% +$897K ﹤0.01% 1645
2018
Q3 		$6.79M Sell
889,392
-52,203
-6% -$351K ﹤0.01% 1971
2018
Q2 		$5.39M Sell
941,595
-56
-0% -$308 ﹤0.01% 2085
2018
Q1 		$4.49M Sell
941,651
-14,842
-2% -$76.3K ﹤0.01% 2035
2017
Q4 		$4.7M Buy
956,493
+343
+0% +$1.66K ﹤0.01% 2022
2017
Q3 		$5.01M Sell
956,150
-74
-0% -$379 ﹤0.01% 1977
2017
Q2 		$5.32M Buy
956,224
+126
+0% +$767 ﹤0.01% 1916
2017
Q1 		$8.03M Sell
956,098
-10,756
-1% -$74.8K ﹤0.01% 1681
2016
Q4 		$6.12M Sell
966,854
-438
-0% -$2.28K ﹤0.01% 1854
2016
Q3 		$4.27M Buy
+967,292
New +$3.86M ﹤0.01% 2081
2016
Q1 		– Sell
-1,106,873
Closed -$11.4M – 3704
2015
Q4 		$11.4M Sell
1,106,873
-92,041
-8% -$915K ﹤0.01% 1418
2015
Q3 		$13.7M Buy
1,198,914
+1,198,552
+331,092% +$16M 0.01% 1313
2015
Q2 		$5K Buy
+362
New +$4.12K ﹤0.01% 4189
2014
Q1 		– Sell
-16,446
Closed -$125K – 4096
2013
Q4 		$125K Buy
16,446
+650
+4% +$4.12K ﹤0.01% 3973
2013
Q3 		$115K Hold
15,796
– – ﹤0.01% 3971
2013
Q2 		$24K Buy
+15,796
New +$27.2K ﹤0.01% 4115

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Invesco's BCRX Position: Q1 2026 in Review

Invesco reduced its BioCryst Pharmaceuticals (BCRX) stake by 3.4% in Q1 2026, selling an estimated $358K and leaving 1,308,813 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Invesco first reported a position in BCRX in Q2 2013 and has held it in 42 quarters since. The position peaked at $14.6M in Q1 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Invesco held 1,308,813 shares of BioCryst Pharmaceuticals worth $12.5M as of Q1 2026.
  • Invesco sold 46,084 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $358K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1714 holding.
  • Invesco first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Invesco's BioCryst Pharmaceuticals position peaked at $14.6M in Q1 2021.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.